## 3 Results  
Of the 43 patients on follow-up, 34 were remotely reviewed (79.1% response rate) between 14 October 2020 and 29 November 2020 and sent back to us their questionnaires (SNOT-22 and sVAS) along with the other information requested. Of the 34 respondents, 21 patients (61.8%) were on intranasal LAS with a median length of LAS treatment of 44 months (range 10-180 months). The median time from sinus surgery to LAS initiation was 16 months (range 3-48 months). Four patients initially tried intranasal LAS but then stopped because of no improvement in their nasal symptoms and were included in the group of patients \"not on LAS\". The remaining patients refused intranasal LAS and did not start any aspirin desensitisation treatment. Similarly, these patients were included in the group of patients \"not on LAS\". Characteristics of the population are reported in Table 1.  
The most affected SNOT-22 domain was \"rhinologic symptoms\" and the question with the highest score (worst symptom) overall was \"loss of smell or taste\". \"Loss of smell or taste\" was also the most frequently ticked \"most important item\" by respondents (20/34; 58.8%), followed by nasal obstruction (12/34; 35.3%), thick nasal discharge (8/34; 23.5%) and post-nasal discharge (8/34; 23.5%) (Figure 1). Only 2 patients, both amongst those using LAS, reported in question 21 of the SNOT-22 that they had \"no problem\" with their \begin{table}
\begin{tabular}{l r r r r} \hline \hline  & \multicolumn{1}{c}{**Whole**} & \multicolumn{1}{c}{**On LAS**} & \multicolumn{1}{c}{**Not on LAS**} & \\  & \multicolumn{1}{c}{**n = 34**} & \multicolumn{1}{c}{**n = 21**} & \multicolumn{1}{c}{**n = 13**} & \multicolumn{1}{c}{**\(p\)-Value**} \\ \hline \multicolumn{5}{l}{_General characteristics_} \\ \hline Age, median [P25–P75], yr & 49.0 [38.0–56.8] & 48.0 [37.0–59.0] & 50.0 [38.0–56.0] & 0.50 \\ \hline Sex, No (\%) & & & & \\ Female & 17 (50.0\%) & 10 (47.6\%) & 7 (53.8\%) & 0.72 \\ Male & 17 (50.0\%) & 11 (52.4\%) & 6 (46.2\%) & \\ Onset CRSwNP, median [P25–P75], yr & 27.0 [18.8–36.8] & 25.0 [17.0–35.0] & 28.0 [24.0–34.5] & 0.39 \\ Onset nasal polyps, median [P25–P75], yr & 30.0 [24.0–40.0] & 31.0 [24.0–41.0] & 30.0 [25.0–38.5] & 0.34 \\ Onset asthma, median [P25–P75], yr & 30.0 [25.0–40.0] & 29.0 [19.5–40.0] & 34.5 [28.5–40.0] & 0.22 \\ Numbers of previous ESS, median [P25–P75] & 3.0 [2.0–4.5] & 3.0 [1.5–3.5] & 4.0 [2.0–5.5] & 0.34 \\ \hline \multicolumn{5}{l}{_Routine medications_} \\ \hline Long-term nasal CS drops, No. (\%) & 32 (94.1\%) & 20 (95.2\%) & 12 (92.3\%) & 0.75 \\ Nasal touc, No. (\%) & 34 (100\%) & 21 (100\%) & 13 (100\%) & 1 \\ ICS, No. (\%) & 12 (35.3\%) & 5 (23.8\%) & 7 (53.8\%) & 0.09 \\ LABA, No. (\%) & 2 (5.9\%) & 1 (4.8\%) & 1 (7.7\%) & 0.75 \\ ICS + LABA, No. (\%) & 19 (55.9\%) & 14 (66.7\%) & 5 (38.5\%) & 0.07 \\ SABA, No. (\%) & 13 (38.2\%) & 7 (33.3\%) & 6 (46.2\%) & 0.52 \\ Anticolinergic inhaler, No. (\%) & 1 (2.9\%) & 0 (0.0\%) & 1 (7.7\%) & 0.21 \\ Long-term macrolides, No. (\%) & 2 (5.9\%) & 1 (4.8\%) & 1 (7.7\%) & 0.75 \\ Antileukotrienes, No. (\%) & 13 (38.2\%) & 9 (42.9\%) & 4 (30.8\%) & 0.41 \\ Oral antihistamines, No. (\%) & 14 (41.2\%) & 9 (42.9\%) & 5 (38.5\%) & 0.71 \\ \hline \multicolumn{5}{l}{_Laboratory findings and testing_} \\ \hline Eosinophils, median [P25–P75], \(\times 109/\) L * & 0.5 [0.4–0.7] & 0.6 [0.4–0.9] & 0.4 [0.3–0.7] & \\ Missing & 11 & 7 & 4 & 0.28 \\ Skin pick test, No (\%) & & & & \\ Negative & 10 (41.7\%) & 4 (19.0\%) & 6 (46.2\%) & \\ One allergen & 3 (12.5\%) & 1 (4.8\%) & 2 (15.4\%) & 0.12 \\ Two allergens & 5 (20.8\%) & 4 (19.0\%) & 1 (7.7\%) & \\ Multiple allergens & 6 (25.0\%) & 5 (23.8\%) & 1 (7.7\%) & \\ Missing & 10 & 7 & 3 & \\ \hline \multicolumn{5}{l}{CRSwNP: chronic rhinosius with nasal polyps; ESS: endoscopic sinus surgery; CS: corticosteroids; ICS: inhaled corticosteroids; LABA: long-acting \(\beta\)2-adrenergic; SABA: short-acting \(\beta\)2-adrenergic; ANCA: antineutrophil cytoplasmic antibodies.} \\ \end{tabular}
\end{table}